Omeros (NASDAQ:OMER) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday morning,Benzinga reports.

Several other equities research analysts have also recently issued reports on the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $7.91 on Tuesday. The business has a 50-day simple moving average of $8.64 and a two-hundred day simple moving average of $7.61. The firm has a market cap of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.03. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently bought and sold shares of OMER. Truvestments Capital LLC grew its stake in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP purchased a new position in shares of Omeros during the 4th quarter valued at $46,000. BNP Paribas Financial Markets boosted its holdings in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management raised its holdings in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares during the period. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.